Liposomal irinotecan
2023-SR-254
Phase 2 small_molecule active
Quick answer
Liposomal irinotecan for Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active